DR. SCOTT E MEYER MD
Prescription History 1306017751
Obstetrics & Gynecology in Mattoon, IL


Quality Rating: 91.8 out of 100 score

NPI Status: Active since March 13, 2008

Contact Information

1000 HEALTH CENTER DR STE 201
MATTOON, IL
ZIP 61938
Phone: (217) 258-4030
Fax: (217) 258-2353

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. SCOTT E MEYER MD, an active Obstetrics & Gynecology specialist practicing in Mattoon, IL. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 52 documented patient claims. Among these therapy options, the most frequently utilized medication is Estradiol, which accounts for 40 claims alone.

Medication Index

No matching medications currently found on file.

Citalopram Hbr

Generic Formulation: Citalopram HydrobromideSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
IL State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills82.6
Peer Average Days Supply2,387
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.4% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $108.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.01

State Avg Cost Per Claim

$8.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A furancarbonitrile that is one of the SELECTIVE SEROTONIN REUPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.

Therapeutic Applications

Citalopram is used to treat depression. It may improve your energy level and feelings of well-being. Citalopram is known as a selective serotonin reuptake inhibitor (SSRI). This medication works by helping to restore the balance of a certain natural substance (serotonin) in the brain.

Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 40
30-Day Fills 58.3
Days Supply 1,749
IL State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills72.6
Peer Average Days Supply2,161
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 37.9% more claims than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,234.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.87

State Avg Cost Per Claim

$95.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. SCOTT E MEYER MD provides transparency into local medical care patterns within Mattoon, IL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Obstetrics & Gynecology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.